Tris Pharma reports positive data from Phase III acute pain therapy trial
Tris Pharma has reported positive topline outcomes from its ALLEVIATE-1 Phase III trial of cebranopadol for treating moderate ...
Targeted Oncology19h
First Dose of CD38-Targeting CAR T-Cell Therapy Administered in AML
The first patient with relapsed/refractory acute myeloid leukemia has received KJ-C2320, an allogeneic CAR T-cell therapy ...
Too Old to Operate1d
Acute Leukemia ICU Admissions Life-Sustaining Therapies and Mortality
The following is a summary of “Critically ill adult patients with acute leukemia: a systematic review and meta-analysis,” published in the January 2025 issue of Critical Care by Chean et al. Researche ...
Medscape2d
EVT Effective, but Use for Acute Stroke Still Low in Europe
Countries committed to rolling out endovascular thrombectomy services are meeting with varying degrees of success.
Patient with severe pneumonia recovers after staying 41 days on ECMO
Gurgaon: A 62-year-old man, Rakesh Kumar Sharma, battling severe viral pneumonia and Acute Respiratory Distress Syndrome (ARDS), who faced exceptional.
Geospatial analysis of stroke centres in India finds stark regional disparities; majority of facilities located in south
Study reveals regional disparities in access to life-saving stroke treatments in India, highlighting urgent need for improved ...
Impacts5d
Understanding Acute Stress Disorder: Signs and Symptoms You Should Know
Life is full of unexpected twists and turns, and while many of these can be managed with resilience, some events are so ...
Healio5d
Retiring executive from The Leukemia & Lymphoma Society still plans to ‘follow the science’
Lee Greenberger, PhD, has retired as The Leukemia & Lymphoma Society’s chief scientific officer after more than a decade in ...
TCTMD7d
Intra-arterial Lytics Don’t Help After Stroke Thrombectomy, but Questions Persist
Two new trials saw no impact of thrombolytics in reducing disability at 90 days, but some positive signals offer hope.
Vertex Pharmaceuticals Sets Sight on Expanding Portfolio with Alyftrek Approval, Pain Treatment Progress, and Diabetes Trials
Vertex secures FDA approval for ALYFTREK and expands TRIKAFTA use, advances diabetes and kidney disease therapies, and ...
Targeted Oncology12d
MRD Monitoring Post-Transplant Predicts Survival in TP53-Mutant MDS/AML
David Sallman, MD, Moffitt Cancer Center, discussed the trial's impact and the future role of MRD monitoring in treatment ...
Taiwan News13d
Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial
The Company’s lead clinical-stage, oral kinase inhibitor tuspetinib (TUS) has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid ...